Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types (for specialized target groups only)
Data presented across 122 adult and pediatric patients (55 patients from primary dataset plus supplementary dataset with 67 additional patients) with TRK fusion cancer across various tumor types / Integrated dataset on larotrectinib demonstrated high overall response rate of 81 percent (63 percent partial responses and 17 percent complete responses), per investigator assessment / For the initial 55 patients, ongoing responses at 12 months improved to 75 percent with longer follow-up; ongoing responses in the supplementary dataset were 81 percent at 12 months; median duration of response not reached at a respective follow-u...
Source: Bayer Company News - October 21, 2018 Category: Pharmaceuticals Source Type: news
U.S. FDA approves Bayer & #8217;s Xarelto ® for patients with coronary or peripheral artery disease (for specialized target groups only)
Xarelto, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease / Xarelto, in combination with aspirin, is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient group / Approval in the U.S. follows regulatory clearance in both Europe and Canada (Source: Bayer Company News)
Source: Bayer Company News - October 12, 2018 Category: Pharmaceuticals Source Type: news
Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027 (for specialized target groups only)
The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical studies / Prophylaxis with BAY94-9027 enables sustained factor VIII concentrations in the blood over time (Source: Bayer Company News)
Source: Bayer Company News - September 21, 2018 Category: Pharmaceuticals Source Type: news
Bayer & #8217;s Jivi ® approved in Japan for hemophilia A (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - September 21, 2018 Category: Pharmaceuticals Source Type: news
Stefan Oelrich to join Bayer Board of Management and head Pharmaceuticals Division
Dieter Weinand leaving the company as of November 1, 2018 / Contract extensions for Board of Management members Liam Condon and Dr. Hartmut Klusik (Source: Bayer Company News)
Source: Bayer Company News - September 13, 2018 Category: Pharmaceuticals Source Type: news
Bayer completes biggest acquisition in its history
Monsanto business included on prorated basis from June 7 / Group sales advance by 8.5 percent (Fx& portfolio adj.) to 9.481 billion euros / EBITDA before special items increases by 3.9 percent to 2.335 billion euros despite unfavorable currency effects / Pharmaceuticals registers higher sales (Fx& portfolio adj.) but lower earnings– substantial increase in R&D investment / Consumer Health business weak again / Crop Science achieves strong increase in sales and earnings after weak prior-year quarter / Animal Health improves sales (Fx& portfolio adj.) and earnings / Net income amounts to 799 million euros / Core earnin...
Source: Bayer Company News - September 5, 2018 Category: Pharmaceuticals Source Type: news
Brazilian court rules that growers will continue to have access to glyphosate
(Source: Bayer Company News)
Source: Bayer Company News - September 3, 2018 Category: Pharmaceuticals Source Type: news
Bayer receives US approval for modern hemophilia A treatment Jivi ® with a step-wise prophylaxis dosing regimen (for specialized target groups only)
Jivi’s extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and further individually adjusted to less or more frequent dosing (Source: Bayer Company News)
Source: Bayer Company News - August 30, 2018 Category: Pharmaceuticals Source Type: news
Bayer submits European marketing authorization application for larotrectinib for the treatment of TRK fusion cancer (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - August 27, 2018 Category: Pharmaceuticals Source Type: news
Bayer secures approval in the EU for Xarelto ® (rivaroxaban) for patients with coronary or peripheral artery disease (for specialized target groups only)
Xarelto is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in patients with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events / Launch first expected in Germany (Source: Bayer Company News)
Source: Bayer Company News - August 24, 2018 Category: Pharmaceuticals Source Type: news
